The Journal of Clinical Endocrinology & Metabolism published a study that shows that  women who take Thiazolidinediones for the treatment of Type-2 diabetes may be at a higher risk for developing bone fractures. The study was conducted by researchers at the Henry Ford Hospital in Michigan frm January 2000 to May 2007 on approximately 19,000 Henry Ford patients. The study included an almost even split of women and men participants.

The study basically found that women were 50% more likely to have a bone fracture after taking thiazolidinedione for one year than patients not on thiazolidinediones and the greatest risk for fractures was for older women, 65 years and older, who were taking thiazolidinedion. The older age group risk factors were perhaps due to the fact that as it is, older women face a higher risk of
osteoporosis and osteoporosis-related fractures, according to researchers at Henry Ford Hospital.

The most interesting part of the study was that the fractures found in women using thiazolidinedione were in the upper and lower extremities. But typically, osteoporosis-related fractures are found in the vertebra and hip.
 
Also, the study found that the men  an increased risk for fractures even if they were taking Thiazolidinedioneson, not even in older men.

All in all, it can be safely concluded that women taking Thiazolidinediones for treating type-2 diabetes must make sure that they talk to their doctors about the increased risks for developing fractures.